Zetiq Reports CE Conformity For Its Cervical Cancer Diagnostic Kit

Main Category: Cervical Cancer / HPV Vaccine
Also Included In: Cancer / Oncology
Article Date: 28 Jul 2010 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


Zetiq Technologies Ltd. ("Zetiq"), a subsidiary of Bio-Light Ltd. (TASE: BOLT), reports that it has fulfilled the essential requirements towards issuing a self declaration CE mark of conformity for its diagnostic product for identification of cervical cancer in cytological specimens.

The requirements fulfilled by the company comply with Council Directive 98/79/EEC for in vitro diagnostic medical devices. As part of these requirements, the Zetiq laboratory has recently received an ISO 13485: 2003 certificate for developing and manufacturing medical products.

The product for which the company issued the CE mark of conformity is positioned at this stage as an adjunct diagnostic test towards identifying cervical cancer in cytological specimens obtained from females undergoing cervical smear examinations by the standard methods.

According to Dr. Adi Elkeles, CEO of Zetiq, "The completion of the requirements towards issuing a CE mark of conformity presents a significant step in the maturation of the company's CellDetect® platform technology to offer diagnostic products. The positive results obtained from the clinical trials performed in the field of cervical cancer, alongside the maturation of our product development, enabled fulfillment of the essential requirements. The recently obtained ISO 13845:2003 certificate for our laboratory constituted another important milestone in reaching this CE mark of conformity, paving the way to enable the company to manufacture its products under the ISO certificate, and continue developing additional products."

The self declaration CE mark of conformity will enable the company to initiate production and marketing of this product in Europe, engage in collaborations with leading companies and laboratories, and perform large scale clinical trials.

Source:
Zetiq Technologies Ltd.

Article adapted by Medical News Today from original press release.
Visit our cervical cancer / hpv vaccine section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Zetiq Technologies Ltd.. "Zetiq Reports CE Conformity For Its Cervical Cancer Diagnostic Kit." Medical News Today. MediLexicon, Intl., 28 Jul. 2010. Web.
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/196000.php>

APA
Zetiq Technologies Ltd.. (2010, July 28). "Zetiq Reports CE Conformity For Its Cervical Cancer Diagnostic Kit." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/196000.php.

Please note: If no author information is provided, the source is cited instead.


Cervical Cancer / HPV Vaccine

Most Popular Articles



Follow Our Cervical Cancer News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Cervical Cancer / HPV Vaccine Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »